Wuhan Bio-Raid Biotechnology

Wuhan Bio-Raid Biotechnology is a leading Chinese biotech company specializing in the research and development of innovative gene and cell therapies—primarily various generations of CAR-T cell products. The company has completed over 800 exploratory clinical studies in hematologic malignancies with targets such as CD19/CD22/CD30/CD20/BCMA/MMSA1/CD99. It claims superior efficacy compared to international benchmarks in blood tumor indications. Notably, it was the first globally to initiate a clinical trial for HIV-targeted GP120 CAR-T cells. Its lead programs are currently in early-stage clinical trials targeting both hematological cancers and solid tumors.